LEN vs RNXT · rev $34.19B vs rev $266.0K
LEN (LEN) versus RenovoRx Inc (RNXT) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
RenovoRx Inc (RNXT) is a biotechnology company listed on US.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
Latest reported RNXT revenue for 2025-09-30 was $266.0K. Net income was -$2.9M. Revenue was down 37.0% from 2025-06-30 to 2025-09-30. RNXT currently screens at market cap $47.0M.
LEN currently screens at market cap $0. RNXT currently screens at market cap $47.0M.
Not investment advice. Open the LEN and RNXT stock pages for the full models.
Not investment advice.